BRAIN Biotech AG publishes solid 9M numbers
Despite further challenging economic conditions and continued R&D investments, parent company, BRAIN Biotech AG today published solid numbers in its 9M 2022/2023 results.
Highlights from BRAIN Biotech AG's announcement:
- 9M Group topline growth +12.3%, +7.9% organic
- BioScience 9M growth +12%, all organic
- Completion of integration of OneBioProducts
BRAIN Biotech AG release strong 9M results despite an increasingly challenging economic environment, BRAIN Biotech remains on track to meet its stated fiscal year targets. In the first nine months of the 2022/23 financial year, the BRAIN Biotech Group generated revenue of € 40.4 million compared to € 36.0 million in the same period of the previous year, which represents growth of 12.3%.
For full information on BRAIN Biotech AG's 9M results and quarterly statement click below.
“The finalisation of the One BioProducts integration will now establish the basis for strong future growth within our products division
